Arpenal tablets 0.05 g

Method of production - tablets (banks) 50 mg

Pharmacotherapeutic group - antispasmodic

Pharmacological action
m-and n-anticholinergic

Ingredients - arpenal 50 mg, excipients (lactose, starch, talc, calcium stearate)

Gastrojejunal ulcer
Pain in the abdomen and pelvis
Pain localized in the upper abdomen
Pain localized to other areas of the lower abdomen
Secondary parkinsonism
Pilorospazm, not elsewhere classified
Renal colic, unspecified
Peptic ulcer unspecified localization
Other diseases of stomach and duodenum
Other and unspecified abdominal pain
Duodenal ulcer
Gastric ulcer

The composition of the components
calcium stearate


White crystalline powder. Very easily soluble in water, soluble in alcohol. Aqueous solutions of hydrolyzed during storage. The structure is very close to spazmolitinu.


Is an antagonist of M-cholinergic receptors and a little more N-cholinergic receptors. Along with the peripheral has a moderate central holinoliticheskoe action. Also has direct spasmolytic (papaverinopodobnoe) effect on smooth muscles.


Applied pilorospazme, gastric ulcer and duodenal ulcer, hepatic and renal colic. In connection with the central cholinolytic effect can be used in parkinsonism. Applied also to decrease the muscle tone in spastic paresis pyramid of different origin (in the recovery period).

Dosage regimen

Assign inside (after eating) for 0,05-0,1 g 2-4 times a day. The course of treatment an average of 3-4 weeks.

Side effects

In case of overdose can appear dizziness, headache, feeling of intoxication (in conjunction with central action), dry mouth (due to peripheral cholinolytic action), breach of accommodation. By providing an irritating effect on the gastric mucosa, spazmolitin may cause dyspeptic symptoms. The feeling of intoxication and dizziness can prevent or reduce the appointment of caffeine (0,1-0,2 g kofeinbenzoata sodium inward or 1 ml of 20% solution under the skin).